388 Studies Now Enrolling
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF COMBINATIONS OF REGN2810 (ANTI-PD-1 ANTIBODY), PLATINUM-BASED DOUBLET CHEMOTHERAPY, AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) VERSUS PEMBROLIZUMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH TUMORS EXPRESSING PD-L1 50%
Study of Combinations of REGN2810, Chemotherapy, and Ipilimumab vs. Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
| Sponsor: | Regeneron Pharmaceuticals, Inc. |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR7798 |
| Contact: | Naiyer Rizvi, MD: 212-305-5098 / nar2144@cumc.columbia.edu |
Additional Study Information:
This study is being done to determine if REGN2810 (anti-PD-1) in combination with ipilimumab (anti-CTLA-4) plus initial platinum-based doublet chemotherapy, or REGN2810 in combination with ipilimumab will prolong how long you live without your disease progressing compared to the standard of care pembrolizumab (anti-PD-1) monotherapy treatment. Neither REGN2810 nor ipilimumab monotherapy are approved for NSCLC by Health Authorities, such as the U.S. Food and Drug Administration (FDA).
This study is closed